Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9609-9618

  Einarsdottir, Berglind O ^a,c   Bagge, Roger Olofsson ^a,c   Bhadury, Joydeep ^a,c   Jespersen, Henrik ^a,c   Mattsson, Jan ^a,c   Nilsson, Lisa M ^a,c   Truvé, Katarina ^d   López, Marcela Dávila ^c,d   Naredi, Peter ^a,c   Nilsson, Ola ^b,c   Stierner, Ulrika ^a,c   Ny, Lars ^a,c   Nilsson, Jonas A ^a,c  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Department of Obstetrics and Gynecology   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Melanoma; Mouse models; Patient derived xenografts

Indexed keywords

3 (2,3 DIHYDROXYPROPYL) 6 FLUORO 5 (2 FLUORO 4 IODOANILINO) 8 METHYLPYRIDO[2,3 D]PYRIMIDINE 4,7 DIONE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; TRAMETINIB; VEMURAFENIB;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DECISION MAKING; DRUG SCREENING; DRUG TARGETING; FEMALE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; MALE; MELANOMA; METASTASIS; MONOTHERAPY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR MODEL; TUMOR XENOGRAFT; VERY ELDERLY; ANIMAL; CASE REPORT; GENETICS; KNOCKOUT MOUSE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; SKIN NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MICE; MICE, KNOCKOUT; MIDDLE AGED; PRECISION MEDICINE; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930432574     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2445     Document Type: Article

References (28)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Jr. et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27:6199-6206.
2. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Jr., Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380:358-365.
3. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366:707-714.
4. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, 3rd, Falchook G, Algazi A, Lewis K, Long GV et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367:1694-1703.
5. Sullivan RJ, Lorusso PM, Flaherty KT. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res. 2013; 19:5283-5291.
6. Bhadury J, Lopez MD, Muralidharan SV, Nilsson LM, Nilsson JA. Identification of tumorigenic and therapeutically actionable mutations in transplantable mouse tumor cells by exome sequencing. Oncogenesis. 2013; 2:e44.
7. Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett. 2014; 344:1-12.
8. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9:338-350.
9. Quintana E, Piskounova E, Shackleton M, Weinberg D, Eskiocak U, Fullen DR, Johnson TM, Morrison SJ. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci Transl Med. 2012; 4:159ra149.
10. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido- Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011; 10:1311-1316.
11. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008; 456:593-598.
12. Bellet RE, Danna V, Mastrangelo MJ, Berd D. Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents. J Natl Cancer Inst. 1979; 63:1185-1188.
13. Fodstad O, Aass N, Pihl A. Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice. Int J Cancer. 1980; 25:453-458.
14. Giovanella BC, Stehlin JS, Jr., Shepard RC, Williams LJ, Jr. Correlation between response to chemotherapy of human tumors in patients and in nude mice. Cancer. 1983; 52:1146-1152.
15. Marshall ES, Finlay GJ, Matthews JH, Shaw JH, Nixon J, Baguley BC. Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst. 1992; 84:340-345.
16. Morelli MP, Calvo E, Ordonez E, Wick MJ, Viqueira BR, Lopez-Casas PP, Bruckheimer E, Calles-Blanco A, Sidransky D, Hidalgo M. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol. 2012; 30:e45-48.
17. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov. 2006; 5:741-754.
18. Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Strom CE, Svensson LM, Schultz N, Lundback T, Einarsdottir BO, Saleh A, Gokturk C, Baranczewski P, Svensson R, Berntsson RP, Gustafsson R et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014; 508:215-221.
19. Forshell LP, Li Y, Forshell TZ, Rudelius M, Nilsson L, Keller U, Nilsson J. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget. 2011; 2:448-460.
20. den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010; 116:1498-1505.
21. Höglund A, Nilsson L, Muralidharan SV, Hasvold LA, Merta P, Rudelius M, Nikolova V, Keller U, Nilsson JA. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res. 2011; 17:7067-7079.
22. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA, 3rd, Messersmith WA, O'Dwyer PJ et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13:782-789.
23. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene. 2006; 25:3357-3364.
24. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20:1297-1303.
25. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38:e164.
26. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D et al. A landscape of driver mutations in melanoma. Cell. 2012; 150:251-263.
27. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. Journal Article. 2014; http://dx.doi.org/10.1101/002832.
28. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010; 11:R106.